Lexotan

Bromazepam, the active ingredient in Lexotan, is a benzodiazepine presented as a tablet for oral use. It treats anxiety disorders, provides short‑term relief of anxiety symptoms, and may be used as an adjunct for insomnia related to anxiety. GNH USA supplies Lexotan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Bromazepam is indicated for anxiety‑related conditions and related central nervous system disorders.

- Anxiety disorders: reduces excessive worry and tension in adults. - Short‑term relief of anxiety symptoms: provides rapid symptom control during acute episodes. - Adjunctive treatment of insomnia related to anxiety: improves sleep continuity when anxiety interferes with sleep.

Bromazepam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness: feeling unusually sleepy or sluggish. - Fatigue: reduced energy and increased tiredness. - Dizziness: sensation of light‑headedness or unsteadiness. - Impaired coordination: difficulty with fine motor tasks.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing, especially with other depressants. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Withdrawal seizures: rare but possible after abrupt discontinuation.

Before prescribing bromazepam, clinicians should consider several safety measures.

- Assess mental health history: evaluate for depression or suicidal ideation before initiating. - Avoid abrupt discontinuation: taper under medical supervision to prevent withdrawal. - Use caution in elderly: increased sensitivity to sedation and falls. - Monitor liver or renal impairment: adjust if necessary. - Avoid alcohol and CNS depressants: risk of additive sedation. - Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Bromazepam can interact with several medications, altering its sedative effect or metabolism.

Major Interactions (Avoid): - Opioids: combined CNS depression may be life‑threatening. - Barbiturates: additive sedation and respiratory depression. - Alcohol: potentiates sedative effects.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may increase risk of serotonin syndrome. - Antihistamines: may enhance drowsiness. - CYP3A4 inhibitors (e.g., ketoconazole): may increase bromazepam plasma levels.